TQB Stock Overview
A biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.29 |
| 52 Week High | US$2.36 |
| 52 Week Low | US$0.29 |
| Beta | 0.27 |
| 11 Month Change | -35.84% |
| 3 Month Change | -53.97% |
| 1 Year Change | -73.87% |
| 33 Year Change | -94.96% |
| 5 Year Change | -87.28% |
| Change since IPO | -92.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| TQB | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -15.2% | 2.2% | 0.2% |
| 1Y | -73.9% | 3.6% | 8.5% |
Return vs Industry: TQB underperformed the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: TQB underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| TQB volatility | |
|---|---|
| TQB Average Weekly Movement | 32.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: TQB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TQB's weekly volatility has increased from 24% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 87 | Jennifer Bath | www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| TQB fundamental statistics | |
|---|---|
| Market cap | €10.33m |
| Earnings (TTM) | -€18.92m |
| Revenue (TTM) | €16.42m |
0.6x
P/S Ratio-0.6x
P/E RatioIs TQB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TQB income statement (TTM) | |
|---|---|
| Revenue | CA$24.09m |
| Cost of Revenue | CA$12.48m |
| Gross Profit | CA$11.61m |
| Other Expenses | CA$39.37m |
| Earnings | -CA$27.76m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 48.20% |
| Net Profit Margin | -115.22% |
| Debt/Equity Ratio | 7.9% |
How did TQB perform over the long term?
See historical performance and comparison